{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cheng YY"],"funding":["NHLBI NIH HHS","NCI NIH HHS"],"pagination":["1180-1193"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12277487"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(7)"],"pubmed_abstract":["Myelin protein zero-like 3 (MPZL3) is an immunoglobulin-containing transmembrane protein with predicted cell adhesion molecule function. Loss of 11q23, in which the MPZL3 gene resides, is frequently observed in cancer. Yet the role and consequences of altered MPZL3 expression have not been explored in tumor development and progression. We addressed this in ovarian cancer, in which both MPZL3 amplification and deletions are observed in respective subsets of high-grade serous specimens. Whereas high and low MPZL3-expressing populations are similarly observed in primary ovarian tumors from an independent patient cohort, metastatic omental tumors largely display decreased MPZL3 expression, suggesting that MPZL3 loss is associated with metastatic progression. MPZL3 knockdown leads to an increas"],"journal":["Cancer research communications"],"pubmed_title":["Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer."],"pmcid":["PMC12277487"],"funding_grant_id":["P30 CA047904","R01 CA242021","T32 HL110849","P50 CA272218"],"pubmed_authors":["Cheng YY","Elhaw AT","Tang PW","Czyzyk TA","Hempel N","Uboveja A","Worley BL","Al-Saad S","Javed Z","White SR","Mythreye K","Kamlapurkar S","Aird KM"],"additional_accession":[]},"is_claimable":false,"name":"Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer.","description":"Myelin protein zero-like 3 (MPZL3) is an immunoglobulin-containing transmembrane protein with predicted cell adhesion molecule function. Loss of 11q23, in which the MPZL3 gene resides, is frequently observed in cancer. Yet the role and consequences of altered MPZL3 expression have not been explored in tumor development and progression. We addressed this in ovarian cancer, in which both MPZL3 amplification and deletions are observed in respective subsets of high-grade serous specimens. Whereas high and low MPZL3-expressing populations are similarly observed in primary ovarian tumors from an independent patient cohort, metastatic omental tumors largely display decreased MPZL3 expression, suggesting that MPZL3 loss is associated with metastatic progression. MPZL3 knockdown leads to an increas","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-03-27T16:19:44.954Z","creation":"2025-08-30T03:05:33.24Z"},"accession":"S-EPMC12277487","cross_references":{"pubmed":["40631617"],"doi":["10.1158/2767-9764.CRC-24-0591"]}}